AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.

BACKGROUND:Leprosy Type 1 reactions are difficult to treat and only 70% of patients respond to steroid treatment. Azathioprine has been used as an immune-suppressant and we tested its efficacy in treating leprosy T1R. METHODOLOGY:Randomised controlled trial adding azathioprine to steroid treatment f...

Full description

Bibliographic Details
Published in:PLOS Neglected Tropical Diseases
Main Authors: Diana N J Lockwood, Joydeepa Darlong, Pitchaimani Govindharaj, Royce Kurian, Pamidipani Sundarrao, Annamma S John
Format: Article in Journal/Newspaper
Language:English
Published: Public Library of Science (PLoS) 2017
Subjects:
Online Access:https://doi.org/10.1371/journal.pntd.0005348
https://doaj.org/article/fae7a6a9f3a04eba97f2559e6ccd80f9
id ftdoajarticles:oai:doaj.org/article:fae7a6a9f3a04eba97f2559e6ccd80f9
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:fae7a6a9f3a04eba97f2559e6ccd80f9 2023-05-15T15:17:59+02:00 AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings. Diana N J Lockwood Joydeepa Darlong Pitchaimani Govindharaj Royce Kurian Pamidipani Sundarrao Annamma S John 2017-03-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0005348 https://doaj.org/article/fae7a6a9f3a04eba97f2559e6ccd80f9 EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC5373510?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0005348 https://doaj.org/article/fae7a6a9f3a04eba97f2559e6ccd80f9 PLoS Neglected Tropical Diseases, Vol 11, Iss 3, p e0005348 (2017) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2017 ftdoajarticles https://doi.org/10.1371/journal.pntd.0005348 2022-12-31T00:49:30Z BACKGROUND:Leprosy Type 1 reactions are difficult to treat and only 70% of patients respond to steroid treatment. Azathioprine has been used as an immune-suppressant and we tested its efficacy in treating leprosy T1R. METHODOLOGY:Randomised controlled trial adding azathioprine to steroid treatment for leprosy reactions. This trial was conducted in four leprosy hospitals in India. Patients with a new leprosy Type 1 reaction affecting either skin or nerve were recruited. They were given a 20 week course of oral prednisolone either with placebo or azathioprine 50mg for 24, 36 or 48 weeks. Outcomes were measured using a verified combined clinical reaction severity score (CCS) and the score difference between baseline and end of study calculated. An intention to treat analysis was done on the 279 patients who had an outcome. PRINCIPAL FINDINGS:345 patients were recruited, 145 were lost due to adverse events, loss to follow up or death. 36% needed extra steroids due to a recurrence of their skin and/or nerve reaction. 76% of patients had improvements in their CCS the end of the study, 22% had no change and 1.1% deteriorated. Adding azathioprine to steroid treatment did not improve CCS. So the improvements were attributable to treatment with steroids. We analysed the skin, sensory and motor scores separately and found that skin improvement contributed most with 78.9% of patients having skin improvement, azathioprine treatment for 48 weeks improved sensory scores it also improved motor scores but so did treatment with prednisolone alone. We identified significant adverse effects attributable to steroid treatment. When azathioprine and Dapsone were given together significant numbers of patients developed significant anaemia. CONCLUSIONS:Azathioprine is not recommended for the treatment of leprosy reactions and does not improve steroid treatment. Recurrent reactions are a major challenge. We have also identified that 65% of patients with sensory and 50% with motor nerve damage do not improve. Future studies should test ... Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic PLOS Neglected Tropical Diseases 11 3 e0005348
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
spellingShingle Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Diana N J Lockwood
Joydeepa Darlong
Pitchaimani Govindharaj
Royce Kurian
Pamidipani Sundarrao
Annamma S John
AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.
topic_facet Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
description BACKGROUND:Leprosy Type 1 reactions are difficult to treat and only 70% of patients respond to steroid treatment. Azathioprine has been used as an immune-suppressant and we tested its efficacy in treating leprosy T1R. METHODOLOGY:Randomised controlled trial adding azathioprine to steroid treatment for leprosy reactions. This trial was conducted in four leprosy hospitals in India. Patients with a new leprosy Type 1 reaction affecting either skin or nerve were recruited. They were given a 20 week course of oral prednisolone either with placebo or azathioprine 50mg for 24, 36 or 48 weeks. Outcomes were measured using a verified combined clinical reaction severity score (CCS) and the score difference between baseline and end of study calculated. An intention to treat analysis was done on the 279 patients who had an outcome. PRINCIPAL FINDINGS:345 patients were recruited, 145 were lost due to adverse events, loss to follow up or death. 36% needed extra steroids due to a recurrence of their skin and/or nerve reaction. 76% of patients had improvements in their CCS the end of the study, 22% had no change and 1.1% deteriorated. Adding azathioprine to steroid treatment did not improve CCS. So the improvements were attributable to treatment with steroids. We analysed the skin, sensory and motor scores separately and found that skin improvement contributed most with 78.9% of patients having skin improvement, azathioprine treatment for 48 weeks improved sensory scores it also improved motor scores but so did treatment with prednisolone alone. We identified significant adverse effects attributable to steroid treatment. When azathioprine and Dapsone were given together significant numbers of patients developed significant anaemia. CONCLUSIONS:Azathioprine is not recommended for the treatment of leprosy reactions and does not improve steroid treatment. Recurrent reactions are a major challenge. We have also identified that 65% of patients with sensory and 50% with motor nerve damage do not improve. Future studies should test ...
format Article in Journal/Newspaper
author Diana N J Lockwood
Joydeepa Darlong
Pitchaimani Govindharaj
Royce Kurian
Pamidipani Sundarrao
Annamma S John
author_facet Diana N J Lockwood
Joydeepa Darlong
Pitchaimani Govindharaj
Royce Kurian
Pamidipani Sundarrao
Annamma S John
author_sort Diana N J Lockwood
title AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.
title_short AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.
title_full AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.
title_fullStr AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.
title_full_unstemmed AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.
title_sort azalep a randomized controlled trial of azathioprine to treat leprosy nerve damage and type 1 reactions in india: main findings.
publisher Public Library of Science (PLoS)
publishDate 2017
url https://doi.org/10.1371/journal.pntd.0005348
https://doaj.org/article/fae7a6a9f3a04eba97f2559e6ccd80f9
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source PLoS Neglected Tropical Diseases, Vol 11, Iss 3, p e0005348 (2017)
op_relation http://europepmc.org/articles/PMC5373510?pdf=render
https://doaj.org/toc/1935-2727
https://doaj.org/toc/1935-2735
1935-2727
1935-2735
doi:10.1371/journal.pntd.0005348
https://doaj.org/article/fae7a6a9f3a04eba97f2559e6ccd80f9
op_doi https://doi.org/10.1371/journal.pntd.0005348
container_title PLOS Neglected Tropical Diseases
container_volume 11
container_issue 3
container_start_page e0005348
_version_ 1766348224873889792